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Introduction 
Nanoparticles  as  one  of  the  most  recent  novel  drug 
delivery  carriers  have  been  shown  to  improve  drug 
efficiency  via  targeting  the  delivery  of  drugs, 
improving the bioavailability and either sustaining the 
release of the drugs or solubilizing them for systemic 
delivery. Additional advantage of this novel technology 
is  the  lower  enzymatic  as  well  as  environmental 
degradation  of  pharmaceutical  active  ingredients. 
1-5 
The main features of nanoparticles, making them ideal 
candidates for drug delivery, are small size and use of 
biodegradable materials in their preparation. Indeed the 
nano-sized  character  of  these  particles  causes  their 
extravagation through the endothelium in inflammatory 
sites, epithelium, tumors, or penetrate microcapillaries 
and  consequently  allows  for  efficient  uptake  by  a 
variety of cell types and selective drug accumulation at 
target sites. 
2,5-8 The use of biodegradable materials for 
nanoparticles  preparation  allows  for  sustained  drug 
release within the target site over a period of days or 
even weeks and thus increases the therapeutic benefit, 
while minimizing side effects. The best-known class of 
biodegradable  materials  for  controlled  release  is  the 
poly  lactide-co-glycolides  (PLGAs).  PLGAs  are 
biocompatible  and  biodegradable  polymers  that  are 
hydrolytically  degraded  into  nontoxic  oligomers  or 
monomers, lactic acid and glycolic acid. 
9-12 
There  have  been  numerous  studies  in  recent  years, 
especially based  on  nanoparticle systems,  in  order  to 
the  targeted  the  delivery  of  antibiotics  toward  the 
infected  cells  as  well  as  enhancing  their 
physicochemical  properties.  Fawaz  and  coworkers 
showed  that  Ciprofloxacin-loaded  nanoparticles  were 
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Purpose:  Azithromycin  (AZI)  is  a  new  macrolide  antibiotic  with  a  better  activity 
against  intracellular  gram  negative  bacteria  in  comparison  with  Erythromycin.  The 
purpose of this research was to prepare AZI nanoparticles (NPs) using PLGA polymer 
and to compare the effectiveness of prepared nanoparticles with untreated AZI solution. 
Methods:  AZI  NPs  were  prepared  by  Modified  Quasi-Emulsion  Solvent  Diffusion 
method. The antibacterial activities of prepared NPs in comparison with AZI solution 
were assayed against indicator bacteria of Escherichia coli (PTCC 1330), Haemophilus 
influenzae (PTCC 1623) and Streptococcus pneumoniae (PTCC 1240) using agar well 
diffusion. Inhibition zone diameters (IZD) of nano-formulation were compared to the 
corresponding untreated  AZI.   Mean  Inhibitory  Concentration (MIC)  values  of  AZI 
were also determined using serial dilution method in nutrient broth medium. Results: 
Mean IZD of nano-formulations for all indicator bacteria were significantly higher than 
that of untreated AZI (P<0.01). The enhanced antibacterial efficacy was more dominant 
in the gram positive species.  The MIC values of NPs against the tested bacteria were 
reduced 8 times in comparison to those of untreated AZI. Conclusion: These results 
indicated an improved potency of AZI NPs which could be attributed to the modified 
surface characteristics as well as increased drug adsorption and uptake.  
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more  active  in  human  macrophages  infected  with 
Mycobacterium avium than  free drug. 
13  In the  other 
study it has been found by Fattal and coworkers that the 
efficacy  of  ampicillin  is  increased  by  120-fold  in 
murine  salmonellosis  by  loading  the  drug  into  the 
nanoparticles. 
14  Moreover Italia and coworkers proved 
that  biodegradable  nanoparticles  improve  oral 
bioavailability  of  amphotericin  B  and  show  reduced 
nephrotoxicity. 
15  
Azithromycin  (AZI)  is  a  new  macrolide  antibiotic 
(Figure 1) that is similar in structure to erythromycin 
with  a  broader  gram-negative  antibacterial  spectrum. 
This drug acts by binding to the 50s ribosomal subunit 
of  susceptible  microorganism  and  interfering  with 
microbial  protein  synthesis. 
16,17  Antimicrobial 
spectrum  of  AZI  is  wide  including  aerobic  gram-
positive microorganism such as Staphylococcus aureus, 
Streptococcus  pneumoniae,  aerobic  gram-negative 
microorganism  such  as  Haemophilus  influenzae  and 
anaerobic  microorganism  such  as  Clostridium 
perfingens  as  well  as  Mycobacteria.  It  worth  to  note 
that  Haemophilus  influenzae  and  Streptococcus 
pneumoniae  are  responsible  for  a  broad  variety  of 
infections such as lower respiratory tract diseases.  
 
Figure 1. Chemical structure of azithromycin 
In our previous study we developed AZI nanoparticles 
and  evaluated  their  physicochemical  properties. 
18  In 
the present work we aimed to evaluate the antibacterial 
activity  of  selected  formulations  with  appropriate 
physicochemical specifications against a group of most 
important  AZI  susceptible  bacteria  including 
Escherichia  coli,  Haemophilus  influenzae  and 
Streptococcus  pneumoniae  in  comparison  with 
untreated azithromycin.  
 
Materials and Methods 
Materials 
AZI  powder  was  obtained  from  Dr  Reddy
,s 
pharmaceutical Company, India. Poly (D,L-lactide-co-
glycolide)  (PLGA)  (50:50  D,L-lactide:glycolide)  with 
average  molecular  weight  of  12,000  g/mol  (Resomer 
RG  502),  was  purchased  from  boehringer  Ingelheim, 
Germany.  Poly  vinyl  alcohol,  PVA,  with  molecular 
weight  of  MW  95000  was  obtained  from  Acros 
Organics  (Geel,  Belgium).  Escherichia  coli 
(PTCC1330),  Haemophilus  influenzae  (PTCC  1623), 
Staphylococcus  aureus  (PTCC  1112)  and 
Streptococcus  pneumoniae  (PTCC  1240)  were 
purchased from Persian Type Culture Collection, Iran. 
Haemophilus  Selective  Agar,  SoyBean  Casein  Digest 
Agar  and  Antibiotic  assay  Medium  were  purchased 
from Merck (Darmstadt, Germany). Blood Base Agar 
media  was  purchased  from  DIFCO,  U.K.  All  other 
materials used were of analytical or HPLC grade. 
 
Preparation of nanoparticles 
Nanoparticles (Nanospheres) were prepared according 
to  our  previously  published  method. 
18  Briefly  NPs 
(nanospheres) with 1:3, 1:2 and 1:1 ratios of the drug to 
PLGA were prepared by nano-precipitation according 
to  the  modified  quasi  emulsion  solvent  diffusion 
technique. AZI and PLGA powders were co-dissolved 
in internal phase containing acetone, 2.5 ml, at room 
temperature (25°C). Typically, different ratios of drug 
and polymer, with the total amount of 100 mg, were co-
dissolved  in  acetone.  The  resulting  organic  solution 
was  injected  at  the  constant  rate  of  0.5  ml/min  in 
aqueous  phase  (40  ml)  containing  PVA  95000  (2% 
w/v), as a stabilizing agent. As water solubility of AZI 
decreases at  higher  pH,  in  order  to  gain  higher  drug 
loading, the pH of aqueous phase was adjusted to 8. 
The process was carried out under homogenization for 
5  min  using  the  Silent  Crusher  M  (Heidolph, 
Germany). The agitation speed was 13000 rpm in an 
ice-water  bath.  Acetone  was  eliminated  at  the  room 
temperature  under  stirring  for  12  h.  The  final  nano-
suspension  was  centrifuged  (Beckman  Centrifuge, 
Avanti
TMJ-25, USA) at 14000 rpm for 30 min and the 
precipitated NPs were washed twice with water, using 
the previously described centrifugation approach, and 
then lyophilized by using a lyophilizer (Christ Alpha 1-
4; Germany). Final dry powder was taken out for anti 
bacterial investigations.  
 
Physicochemical  characterization  of  AZI  loaded 
nanoparticles 
The mean particle-size values of NPs were measured 
by using a laser diffraction particle-size analyzer (Sald 
2101, Shimadzu, Japan) equipped with Wing software 
(version  1.20).  The  morphology  of  the  NPs  were 
investigated  by  scanning  electron  microscopy  (SEM) 
(LEO 440i, Leo Electron Microscopy Ltd, Cambridge, 
UK) at an accelerating voltage of 20 kV. In order to 
determine  the  encapsulation  efficiency  of  NPs,  three 
samples were dissolved in acetone, after evaporation of 
the acetone the  drug was  dissolved in  100 ml  sterile 
water. 
3,5,19 The mixture was then centrifuged and the 
supernatant was drawn to measure their AZI contents 
microbiologically  after  appropriate  dilution.  A 
microbiological  assay  was  adapted  from  the  method 
described  in  the  official  US  Pharmacopoeia  (USP 
2004)  monograph.  The  X-ray  powder  diffraction 
(XRPD) of the drug, PLGA, NPs and physical mixture  
|   19 
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in the 1:2 drug to polymer ratio were recorded using an 
automated  X-ray  diffractometer  (Siemens  D5000, 
Munich,  Germany).  Drug  release  was  performed  in 
sink conditions according to our previously published 
method. 
18  
 
Antibacterial activity of the nanoparticle suspensions 
The NPs antimicrobial activity was compared with that 
of the free drug by means of well diffusion method as 
well  as  broth  serial  dilution  method  using  E.  coli 
(PTCC  1330),  H.  influenzae  (PTCC  1623),  S. 
pneumoniae (PTCC 1240) and S. aureus (PTCC 1112). 
All  the  bacteria  were  purchased  from  Persian  type 
culture collection. The bacteria obtained in lyophilized 
form were activated according to their manufacturer’s 
protocol.  At  first,  their  stock  samples  that  contained 
20٪ glycerol were prepared from activated bacteria and 
kept at freezer for further uses. The activated E. coli, H. 
influenzae, S. aureus and S. pneumoniae were cultured 
in  Soy  Bean  Casein  Digest  Agar,  Haemophilus 
Selective Agar, Nutrient Broth and Blood Base Agar 
medium respectively (24 hours before studies).  
The antibacterial activity of the selected formulations 
as  well  as  control  samples  was  evaluated  using  agar 
well  diffusion  and  broth  dilution  method. 
20  In  agar 
well  diffusion  method,  firstly  appropriate  amount  of 
prepared inoculum of each bacterium, were transferred 
into  its  selective  medium.    Soy  Bean  Casein  Digest 
Agar medium was used for culturing E. coli. Also H. 
influenzae and S. pneumoniae were transferred on the 
surface of Haemophilus Selective Agar and Blood Base 
Agar  respectively.  Wells  with  8-mm  diameters  were 
punched on the surface of agar media using a sterile 
cork borer. Aliquots of 100 µl of each sample (1:3, 1:2 
and 1:1 AZI to PLGA nanoparticles) were transferred 
into the wells. After incubation at 37 °C for 24 hours, 
the inhibition zones around the wells were measured in 
using zone reader. In order to evaluate the MIC of NPs 
the  mentioned  nanoparticle  suspensions  were  serially 
diluted.  The  tubes  were  inoculated  with  a  1ml  of 
inoculums  of  tested  bacterium  (final  concentration  of 
10
5-10
6 CFU/ml). After 24 h of incubation at 37°C, the 
tubes  were  screened  for  any  evidence  of  bacterial 
growth. MIC was defined as the lowest concentration 
of AZI that completely suppressed the bacterial growth. 
21 PLGA nanoparticles without AZI and untreated AZI 
were  applied  as  positive  and  negative  controls 
respectively. 
 
Statistical analysis 
One-way  analysis  of  variance  (ANOVA)  was 
performed for comparison of the results. P values of 0 
< 0.01 were considered significant. 
 
Results and discussion 
Physicochemical  properties  of  AZI  loaded 
nanoparticles 
Based  on  our  previously  published  paper,  the 
submicron particles ranging from 212 to 252 nm with 
Narrow  range  of  size  (Figure  2),  a  relatively 
monodisperse  distribution  with  spherical  morphology 
(Figure  3)  were  achieved  using  modified  quasi 
emulsion  solvent  diffusion  technique.    Results  also 
indicated a maximum AZI loading of about 78.5٪ with 
an increasing manner with increase in the proportion of 
PLGA. This observation may be attributed to the higher 
viscosity of the internal organic phase for higher PLGA 
ratios,  which  in  turn  would  decrease  the  diffusion 
coefficient of the drug. Furthermore at higher polymer 
ratio the extent of drug loss during washing procedure 
will be less.  
 
Figure 2. Particle size distribution of nanoparticles preparation 
with 1:3 ratios of the drug to PLGA ratio. 
 
XRPD  patterns  of  NPs  were  characterized  by  the 
complete absence of any diffraction peaks, suggesting a 
complete amorphization of AZI in the NPs. 
18 Based on 
the results from release study the release rate of AZI 
from NPs was slower and more sustained than that of 
intact AZI that may be due to the presence of insoluble 
polymer (PLGA) in the NPs matrix body which in turn 
reduces  the  water  penetration,  hence  dissolution  and 
diffusion 
22-24 (data not shown). 
18  
 
Antimicrobial activity of AZI loaded nanoparticles 
To  evaluate  the  antibacterial  activity  of  the  selected 
nano  formulations  and  untreated  AZI  samples,  agar 
diffusion  method  and  broth  dilution  method,  that  is 
highly  recommended  methods  for  testing  of 
antimicrobial  agents  against  fastidious  organisms  like 
Haemophilus  spp.  and  streptococci,  were  performed 
based on NCCLS guideline with some modifications as 
described  in  material  and  method  section.  Mean 
inhibitory  diameters  related  to  each  of  the  nano 
formulation of AZI were compared to their untreated 
counterparts in the same concentrations using ANOVA. 
Figure  4  to  Figure  6  illustrate  and  compare  mean 
inhibitory diameters related to AZI nonoparticles with 
untreated samples against E. coli, H. influenzae and S. 
pneumoniae respectively. As it can be seen there are  
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Figure 3. SEM images of azithromycin loaded nanoparticles of the (A) 1:2 (B) 1:3 drug to polymer ratios. 
 
significant  differences  between  inhibitory  zone 
diameters of samples. For instance the concentration of 
100 µg/ml of untreated AZI produced mean inhibitory 
diameter of about 20 mm, whereas AZI nanoparticles 
showed the same mean inhibitory diameter (20 mm) in 
the  concentration  of  12.5  µg/ml  indicating  8  times 
reduction in the AZI concentration to achieve the same 
antibacterial  activity  against  E.  coli  (Figure  4).  In  a 
same manner as shown in Figure 5 and 6 the activities 
of  AZI  nanoparticles  were  considerably  enhanced 
against H. influenzae and S. pneumoniae compared to 
their  untreated  counterparts.    As  the  first  inhibitory 
diameters appear in the concentrations of 25 µg/ml and 
3.12 µg/ml for untreated AZI against H. influenzae as 
well as S. pneumoniae respectively, they shift to 3.12 
µg/ml  and  0.19  µg/ml  when  AZI  nanoparticles  were 
applied,  showing  8  and  16  times  reductions  in  the 
required  AZI  concentrations  for  producing  the  same  
|   21 
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action  against  H.  influenzae  And  S.  pneumoniae 
respectively.  Table 1 show the mean MIC of the nano 
formulation and untreated AZI against  E. coli and S. 
aureus. The lowest inhibitory concentration were about 
0.78 µg/ml and 0.39 µg/ml regardless of the ratio of 
drug:polymer in nanoparticle suspension, whereas the 
inhibitory  concentration  were  about  6.25  µg/ml  and 
3.12  µg/ml  for  the  corresponding  Untreated  AZI 
solution in E. coli and S. aureus respectively, indicating 
8 times reduction in AZI MIC. Blank NPs indicated no 
antibacterial  activity  against  indicated  bacteria.  Also 
the  ratio  of  polymer  used  had  no  influence  on  the 
antibacterial activity  of  the nanoparticles,  at  least  for 
the indicator bacteria examined here (P>0.01).  It also 
worth to note that among three indicator bacteria tested 
in this study the activity of prepared nano formulations 
against gram positive S. pneumoniae were remarkably 
better  than  gram  negative  species  of  E.  coli  and  H. 
influenza.  This  could  be  because  of  some  possible 
mechanisms; one is the fact that presence of a double 
membrane  could  exclude  certain  structures  from 
penetrating the cell, partially accounting for why gram 
negative  bacteria  are  generally  more  resistant  to 
antibiotics  than  other  gram  positive  bacteria. 
25
 
Table 1. Minimum inhibitory concentration (MIC) of untreated AZI solution (AZI), physical mixtures (PM) and 
AZI-loaded nanoparticles with different drug:polymer ratios against E. coli and S. aureus 
  MIC (µg/ml) 
Sample  E. coli  S. aureus 
AZI  6.25  3.12 
PM 1:1  6.25  3.12 
PM 1:2  6.25  3.12 
PM 1:3  6.25  3.12 
NANO 1:1  0.78  0.39 
NANO 1:2  0.78  0.39 
 
 
 
Figure 4. Inhibition zone diameter of azithromycin loaded nanoparticles in plates with E.coli inoculums 
(NANO 1:1 (F1), NANO 1:2 (F2), NANO 1:3 (F3)) 
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Figure 5. Inhibition zone diameter of azithromycin loaded nanoparticles in plates with H. influenza inoculums                                         
(NANO 1:1 (F1), NANO 1:2 (F2), NANO 1:3 (F3)) 
 
 
 
 
Figure 6.Inhibition zone diameter of azithromycin loaded nanoparticles in plates with S. pneumonia inoculum                                         
(NANO 1:1 (F1), NANO 1:2 (F2), NANO 1:3 (F3)) 
 
 
Conclusion 
The  present  study  was  conducted  to  evaluate  the 
antibacterial  activity  of  AZI-PLGA  nanoparticles 
against  E.  coli,  H.  influenzae,  S.  aureus  and  S. 
pneumoniae which are important species susceptible to 
AZI.  The  obtained  results  indicate  that  there  is  a 
significant enhancement in the efficacy of AZI loaded 
nano formulations in comparison with untreated AZI in 
the  same  concentration.  The  improved  efficacy  of 
pharmaceutical active products when prepared in nano 
formulations  have  been  repeatedly  reported  so  far. 
There are also numerous studies to enhance antibiotics 
efficacies  against  their  indicator  microorganisms 
exploiting  the  nano  technology  that  showed  better 
activities. 
10,13,14 This may be due to the several reasons 
more dominantly facilitated penetration of drug in nano 
particle form into the bacterial cells; and better delivery 
of  the  drug  to  its  site  of  action 
10  as  well  as  higher 
stability of the drug in nano encapsulated form against 
rapid enzymatic/hydrolytic degradation. 
26   
Adhesion of the NPs to the bacterial cell wall can be 
another mechanism for greater antibacterial activity of  
|   23 
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the NPs in comparison with pure drug. This adhesion 
could provide a sustained antimicrobial activity of the 
drug incorporated against the target organisms. 
27-29  
In  conclusion,  Azithromycin-loaded  poly  (lactide-co-
glycolide)  (PLGA)  nanoparticles  (NPs)  were  more 
effective  than  untreated  AZI  against  E.  coli,  H. 
influenzae, S. aureus and S. pneumonia. Therefore, the 
clinical  effectiveness  of  azithromycin  might  be 
enhanced  if  its  nanoparticles  are  incorporated  in  the 
dosage  forms  e.g.  aerosol,  ocular,  topical  and  oral 
preparations  as  colloidal  drug  delivery  system 
compared  to  the  conventional  formulation  of 
azithromycin present in the market. 
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